No abstract available.
Dermoscopy* ; Diagnosis

The prenatal diagnosis of spina bifida includes the combined use of maternal serum alpha-fetoprotein (MSAFP) screening and fetal sonography. On ultrasonogram, spina bifida is characterizd by visualization of the spinal defect and associated cranial abnomalities: the Lemon sign, the Banana sign, ventriculomegaly, small biparietal diameter, and obliteration of the cisterna magna. We should now be able to rely on ultrasound as the main technique for diagnosis of spina bifida when MSAFP is elevated. Recently, we have experienced three cases of spina bifida diagnosed with meningomyelocele, lemon sign, banana sign and ventriculomegaly on ultrasonogram at respectively 18+3, 18, and 18+6 weeks of gestation. We present these cases with a brief review of literatures.
alpha-Fetoproteins ; Cisterna Magna ; Diagnosis ; Mass Screening ; Meningomyelocele ; Musa ; Pregnancy ; Prenatal Diagnosis ; Spinal Dysraphism* ; Ultrasonography*

No abstract available.
Hair Follicle* ; Hair* ; Nevus*

We have shown that hyaluronic acid stimulates the proliferation of quiescent NIH 3T3 cells. We have shown that treatment of 1 mg/ml hyaluronic acid results in increase of tyrosine phosphorylation of two proteins, MW 124 kDa and 60 kDa as detected by anti-tyrosine antibodies by Western blot analysis. Maximum phosphorylation occurred within 2 h after addition of 1 mg/ml hyaluronic acid. Stimulation of proliferation was also accompanied by increase in c-Myc protein, which was inhibited by amlloride, an inhibitor of Na+/H+ antiporter and EGTA and increase in the steady state level of pRb, the RB gene product. These results suggest that the intracellular signal transduction pathways that mediate the stimulatory effects of hyaluronic acid on cellular proliferation are similar to those of growth factors.
3T3 Cells ; Amiloride/pharmacology ; Animal ; Cell Division ; Dose-Response Relationship, Drug ; Egtazic Acid/pharmacology ; Hyaluronic Acid/pharmacology* ; Mice ; Mitogens/pharmacology* ; Phosphoproteins/metabolism* ; Phosphorylation ; Proto-Oncogene Proteins c-myc/metabolism* ; Retinoblastoma Protein/metabolism* ; Signal Transduction ; Sodium-Hydrogen Antiporter/antagonists & inhibitors ; Tyrosine

PURPOSE: A prospective randomized controlled trial was performed to investigate the effects of intravenous hydration, both with and without diuretics, on the fragmentation and passage of an upper ureteral stone during ESWL. MATERIALS AND METHODS: We analyzed 65 patients with upper ureteral stones, primarily treated with piezoelectric LT-02 lithotripter, between November, 2001 and March, 2002. The patients were divided in 3 groups; the 20 patients in group A were injected with 500ml of normal saline for intravenous hydration, and 20mg of furosemide for diuretic effect during the ESWL; the 20 patients in group B were injected with normal saline without furosemide, and the remaining 25, group C, were used as controls. The same energy settings for the shockwaves in one session were equally applied to all the patients during the ESWL, with a 4Hz shockwave frequency, 100% power, a 50 minute treatment and 43 minute storage time. After 2 weeks, the degrees of stone fragmentation, and the residual fragments, were evaluated on the post-ESWL KUB and compared with the pre-ESWL KUB. RESULTS: After a single ESWL treatment, the stone-free rate was 70% (14 of 20 patients) in group A, 60% (12 of 20 patients) in group B and 28% (7 of 25 patients) in group C (p<0.05). The stone-free rates of groups A and B were significantly higher than that of group C, but there was no statistical difference between groups A and B. The stone-free rates, after a single session, according to the stone size was higher in groups A (77.8%) and B (73.3%) than in group C (38.9%) for stones smaller than 10mm (p<0.05), but they were similar between the three groups for stones larger than 10mm (p>0.05). CONCLUSIONS: Intravenous hydration with normal saline, both with and without a furosemide injection for diuretic effect, during ESWL would be an effective method to facilitate the fragmentation and passage of upper ureteral stones smaller than 10mm.
Diuretics* ; Furosemide ; Humans ; Lithotripsy* ; Prospective Studies ; Shock* ; Ureter* ; Ureteral Calculi

No abstract available.
Uterine Prolapse*

No abstract available.
Urinary Tract Infections* ; Urinary Tract*

No abstract available.
Calcinosis*

BACKGROUND: In this study, we identified the cutoff value for the percentage in body fat related to metabolic syndrome in elderly people with normal body mass index (BMI). We also found the correlation between body fat percentage and metabolic syndrome. METHODS: We used data from the Korean National Health and Nutrition Examination Survey conducted from 2008 to 2011. Our subjects were elderly people aged 65 or above, with BMI less than 23.0 kg/m2. We determined the cutoff value for body fat percentage through receiver operating characteristic analysis. RESULTS: The cutoff value for percentage body fat related to metabolic syndrome was 19.5% for men (sensitivity 68.0%, specificity 62.9%) and 30.0% for women (sensitivity 55.1%, specificity 62.0%). Based on the cutoff value, 43.3% in men and 43.1% in women were classified into the high body fat percentage group. After adjusting for age, smoking status, alcohol consumption, and exercise status, the men with higher than normal body fat percentage had an odds ratio of 3.61 (95% confidence interval [CI], 2.10-6.22; p<0.001) for developing metabolic syndrome, whereas women had an odds ratio of 1.95 (95% CI, 1.30-2.92; p<0.001). CONCLUSION: The cutoff value for body fat percentage related to metabolic syndrome was lower in elderly. In the elderly with normal body mass index, high percentage of body fat percentage was associated with a high risk of metabolic syndrome.
Adipose Tissue* ; Aged* ; Alcohol Drinking ; Body Mass Index ; Female ; Humans ; Ideal Body Weight* ; Male ; Nutrition Surveys ; Obesity ; Odds Ratio ; ROC Curve ; Sensitivity and Specificity ; Smoke ; Smoking

No abstract available.
Animals ; Apoptosis* ; Collagen* ; Insulin* ; Rats* ; Streptozocin*